Evidence that antihuman tumor necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome
B CHARPENTIER, C HIEssE, O LANTZ… - …, 1992 - journals.lww.com
Transplantation, 1992•journals.lww.com
We have used an antihuman tumor necrosis factor monoclonal antibody, CB006 (murine
IgG1), to prevent the OKT3-induced acute clinical syndrome. This syndrome is due to the
massive, although transient release in the circulation of various cytokines (TNF, interferon
gamma, interleukin 2, interleukin 6) and represents one important side effect linked to in vivo
use of OKT3. Fourteen kidney allograft recipients undergoing prophylactic OKT3 therapy
were treated with CB006 in a single iv injection of either 0.4 mg/kg (group I, 7 patients) or 2 …
IgG1), to prevent the OKT3-induced acute clinical syndrome. This syndrome is due to the
massive, although transient release in the circulation of various cytokines (TNF, interferon
gamma, interleukin 2, interleukin 6) and represents one important side effect linked to in vivo
use of OKT3. Fourteen kidney allograft recipients undergoing prophylactic OKT3 therapy
were treated with CB006 in a single iv injection of either 0.4 mg/kg (group I, 7 patients) or 2 …
Abstract
We have used an antihuman tumor necrosis factor monoclonal antibody, CB006 (murine IgG1), to prevent the OKT3-induced acute clinical syndrome. This syndrome is due to the massive, although transient release in the circulation of various cytokines (TNF, interferon gamma, interleukin 2, interleukin 6) and represents one important side effect linked to in vivo use of OKT3. Fourteen kidney allograft recipients undergoing prophylactic OKT3 therapy were treated with CB006 in a single iv injection of either 0.4 mg/kg (group I, 7 patients) or 2 mg/kg (group II, 7 patients), 1 hr before the first OKT3 administration. Nineteen consecutive patients formed a historical control group.
Lippincott Williams & Wilkins